# FDA Grants Our End of Phase 2 Meeting Request | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/319473
- Entity ID: wefunder:feed_item:319473
- Published at: 2026-05-11 15:09:16 UTC
- Updated at: 2026-05-25 05:17:48 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors & Community,The FDA has granted our End-of-Phase 2 meeting request for SJP-001, scheduled for July 1.Following this meeting, we expect to receive the official FDA meeting minutes in August — a critical regulatory milestone that will help define the path from Phase 3 through New Drug Application.This is the pivotal conversation: the meeting where FDA and Sen-Jam review the totality of our data to date and align on the development plan for SJP-001.We are addressing a WHO-classified disease affecting hundreds of millions of people worldwide, in a multi-billion-dollar consumer market currently dominated by supplements — many of which lack proven clinical efficacy and, in some cases, may lack the legal standing to make the claims they promote.Sen-Jam is stepping into that gap with real science, real data, and a regulated pharmaceutical development path.Tomorrow, we submit the proof: a comprehensive FDA briefing document our team has worked tirelessly to produce. It lays out the scientific, clinical, and regulatory case for why SJP-001 deserves to advance. We believe it makes that case compellingly.More than ten FDA reviewers across Clinical, Pharmacology, Toxicology, and Clinical Outcome Assessment have been assigned to our meeting. That level of cross-functional engagement signals that FDA is taking this conversation seriously.This milestone belongs to everyone in this room.Your early belief in a problem the pharmaceutical world largely ignored is exactly what helped put us here. The work has always been worthy of the support — and now the FDA is formally in the conversation.Let's do this.Jim